Insider Selling: Definium Therapeutics (NASDAQ:DFTX) Insider Sells 3,097 Shares of Stock

Definium Therapeutics, Inc. (NASDAQ:DFTX) insider Matthew Wiley sold 3,097 shares of the business’s stock in a transaction dated Friday, September 25th. The stock was sold at an average price of $36.57, for a total transaction of $113,257.29. Following the sale, the insider directly owned 359,036 shares in the company, valued at $13,129,946.52. This trade represents a 0.86% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Definium Therapeutics Stock Down 0.5%

Shares of NASDAQ DFTX traded down $0.20 during mid-day trading on Tuesday, hitting $38.21. The company had a trading volume of 1,967,182 shares, compared to its average volume of 2,245,960. The company has a current ratio of 6.95, a quick ratio of 6.95 and a debt-to-equity ratio of 0.04. The firm has a 50-day simple moving average of $41.37 and a two-hundred day simple moving average of $32.06. The company has a market capitalization of $5.13 billion, a PE ratio of -11.14 and a beta of 2.23. Definium Therapeutics, Inc. has a one year low of $10.46 and a one year high of $49.70.

Definium Therapeutics (NASDAQ:DFTX) last released its earnings results on Thursday, August 6th. The company reported ($1.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by ($0.89). On average, equities analysts expect that Definium Therapeutics, Inc. will post -3.02 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the company. Maxim Group set a $55.00 price objective on Definium Therapeutics and gave the company a “buy” rating in a report on Friday, August 14th. Needham & Company LLC restated a “buy” rating and set a $66.00 price objective on shares of Definium Therapeutics in a research note on Monday, September 14th. HC Wainwright reaffirmed a “buy” rating and issued a $70.00 target price on shares of Definium Therapeutics in a report on Monday, September 14th. Citigroup reiterated a “buy” rating on shares of Definium Therapeutics in a research note on Monday, June 22nd. Finally, Wells Fargo & Company boosted their price target on Definium Therapeutics from $68.00 to $72.00 and gave the stock an “overweight” rating in a research report on Thursday, August 13th. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Definium Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $64.88.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Avoro Capital Advisors LLC acquired a new stake in Definium Therapeutics during the fourth quarter worth approximately $66,950,000. Wellington Management Group LLP acquired a new position in shares of Definium Therapeutics in the second quarter valued at approximately $138,755,000. Seven Fleet Capital Management LP acquired a new position in shares of Definium Therapeutics in the second quarter valued at approximately $6,992,000. Platinum Investment Management Ltd. bought a new position in shares of Definium Therapeutics during the fourth quarter worth approximately $937,000. Finally, TD Waterhouse Canada Inc. bought a new position in shares of Definium Therapeutics during the second quarter worth approximately $1,592,000. 27.91% of the stock is owned by institutional investors.

About Definium Therapeutics

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.